New England Capital Financial Advisors LLC Gilead Sciences, Inc. Transaction History
New England Capital Financial Advisors LLC
- $177 Billion
- Q1 2024
A detailed history of New England Capital Financial Advisors LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, New England Capital Financial Advisors LLC holds 666 shares of GILD stock, worth $44,348. This represents 0.03% of its overall portfolio holdings.
Number of Shares
666
Previous 663
0.45%
Holding current value
$44,348
Previous $53.7 Million
9.06%
% of portfolio
0.03%
Previous 0.03%
Shares
6 transactions
Others Institutions Holding GILD
# of Institutions
1,885Shares Held
1BCall Options Held
8.71MPut Options Held
8.02M-
Black Rock Inc. New York, NY123MShares$8.16 Billion0.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$7.64 Billion0.17% of portfolio
-
Capital World Investors Los Angeles, CA84.5MShares$5.63 Billion1.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.2MShares$4.08 Billion1.05% of portfolio
-
State Street Corp Boston, MA57.7MShares$3.84 Billion0.19% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $83.5B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...